- YD Biopharma Limited reported a **9% decrease in net revenue** to **$204,007** for the six months ended June 30, 2025, down from $224,980 in the prior year.  **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:0]** **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:1]** **[2011674_0001213900-25-093988_ea025743901ex99-2_ydbio.htm:1]** **[2011674_0001213900-25-093988_ea025743901ex99-3_ydbio.htm:3]** 
- The company's net loss significantly increased to **$(1,916,581)** for the six months ended June 30, 2025, compared to $(165,364) in the prior period, primarily due to higher general and administrative and research and development expenses.  **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:1]** **[2011674_0001213900-25-093988_ea025743901ex99-2_ydbio.htm:1]** **[2011674_0001213900-25-093988_ea025743901ex99-3_ydbio.htm:3]** 
- Cash and cash equivalents for YD Biopharma Limited decreased to **$469,520** as of June 30, 2025, from $3,132,298 at December 31, 2024.  **[2011674_0001213900-25-093988_ea025743901ex99-2_ydbio.htm:0]** **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:1]** 
- YD Bio Limited completed its business combination with Breeze Holdings Acquisition Corp. in **August 2025**, becoming a publicly traded company and securing **$13.2 million** in gross proceeds from a concurrent PIPE financing.  **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:0]** **[2011674_0001213900-25-093988_ea025743901ex99-1_ydbio.htm:7]** 
- The company is advancing its pipeline with new projects, including initiating clinical trial applications in 2025 for exosome-based contact lenses and artificial tears for dry eye symptoms, and expanding into oncology diagnostics with a pancreatic cancer early detection technology.  **[2011674_0001213900-25-093988_ea025743901ex99-3_ydbio.htm:0]** **[2011674_0001213900-25-093988_ea025743901ex99-7_ydbio.htm:1]**

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results and Business Combination Completion

- YD Bio Limited successfully completed its business combination with Breeze Holdings Acquisition Corp. and began trading its common stock and warrants on the Nasdaq Global Market under the ticker symbols **"YDES"** and **"YDESW"** on **August 29, 2025**.  **[2011674_20250829HK61800:0]** 
- The company expects to yield **more than $11,500,000** from the PIPE offering and cash released from the trust, after business combination closing-related expenses, to fund future operations.  **[2011674_20250829HK61800:0]** 
- YD Bio Ltd. is a biotechnology company focused on advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, with core programs including blood-based cancer detection, stem cell- and exosome-based ophthalmology therapies, and clinical trial and ancillary services.  **[2011674_20250829HK61800:0]** 
- Dr. Ethan Shen, Chairman of the Board and Chief Executive Officer, stated that becoming a publicly traded Nasdaq-listed company enables the company to accelerate its mission of delivering innovative solutions.  **[2011674_20250829HK61800:1]**

YD Bio (YDES)